Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding
Quality Report Card click to collapse
From Analysis:
What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?
Hypotheses from Same Analysis (8)
These hypotheses emerged from the same multi-agent debate that produced this hypothesis.
Description
Background and Rationale
Parkinson's disease (PD) is characterized by the accumulation of misfolded α-synuclein aggregates, primarily in the form of Lewy bodies and Lewy neurites. While the precise mechanisms underlying α-synuclein aggregation remain incompletely understood, emerging evidence suggests that the gut-brain axis plays a crucial role in PD pathogenesis. The "Braak hypothesis" proposes that α-synuclein pathology originates in the enteric nervous system and spreads to the central nervous system via the vagus nerve, supported by observations that vagotomy reduces PD risk. Recent discoveries have revealed that certain gut bacteria produce amyloid proteins called curli fibrils, which exhibit striking structural similarities to human α-synuclein.
...Figures & Visualizations
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
graph TD
A["Gut Microbiome<br/>E. coli and Salmonella<br/>Enterobacteriaceae"] --> B["CsgA Gene Expression<br/>Curli-specific Gene A<br/>Bacterial Amyloid Precursor"]
B --> C["CsgA Protein Production<br/>Unfolded Monomeric Form<br/>Cytoplasmic Assembly"]
C --> D["CsgB Nucleation<br/>Extracellular Secretion<br/>Fibril Initiation"]
D --> E["Curli Fibril Formation<br/>Beta-sheet Rich Structure<br/>Cross-beta Architecture"]
E --> F["Bacterial Biofilm Matrix<br/>Adhesion and Colonization<br/>Gut Epithelial Interface"]
F --> G["Intestinal Barrier<br/>Disruption<br/>Increased Permeability"]
G --> H["Curli Fibril Translocation<br/>Systemic Circulation<br/>Molecular Mimicry"]
H --> I["Enteric Nervous System<br/>Myenteric Plexus<br/>Initial Contact Site"]
I --> J["Alpha-synuclein Cross-seeding<br/>Template-directed Misfolding<br/>Prion-like Propagation"]
J --> K["Alpha-synuclein Aggregation<br/>Oligomer Formation<br/>Toxic Species Generation"]
K --> L["Vagus Nerve Transmission<br/>Retrograde Axonal Transport<br/>CNS Propagation"]
L --> M["Brainstem Pathology<br/>Dorsal Motor Nucleus<br/>Locus Coeruleus"]
M --> N["Substantia Nigra<br/>Dopaminergic Neuronal Loss<br/>Lewy Body Formation"]
N --> O["Motor Dysfunction<br/>Parkinson Disease<br/>Clinical Manifestation"]
P["CsgA Targeting Therapy<br/>Curli Inhibition<br/>Preventive Strategy"] --> E
Q["Microbiome Modulation<br/>Probiotic Intervention<br/>Bacterial Competition"] --> A
R["Vagotomy<br/>Nerve Transection<br/>Pathway Interruption"] --> L
classDef normal fill:#4fc3f7
classDef therapeutic fill:#81c784
classDef pathology fill:#ef5350
classDef outcome fill:#ffd54f
classDef molecular fill:#ce93d8
class A,B,C,D,E,F normal
class P,Q,R therapeutic
class G,H,I,J,K,L,M,N pathology
class O outcome
Dimension Scores
Legacy Card View — expandable citation cards
✓ Supporting Evidence 9
Examines computational interference with E. coli CsgA amyloid assembly, which aligns with the hypothesis of di… MEDIUM▼
The adhesion of bacterial cells through extracellular matrices plays a critical role in biofilm formation. Disrupting these matrices offers a promising strategy to overcome the persistent challenge of eradicating biofilms associated with chronic infections. CsgA, a major functional amyloid within the extracellular matrix of Escherichia coli (E. coli), adopts a β-sheet-rich conformation that contributes to the structural integrity of biofilms. The stability of these β-sheets is maintained by an e
Identifies a protein that inhibits CsgA amyloid assembly in E. coli, directly supporting the concept of preven… MEDIUM▼
Functional amyloids are a class of amyloids that serve important biological functions. One such bacterial functional amyloid is curli, assembled on the cell surface by Escherichia coli during biofilm biogenesis. Curli precursor proteins, CsgA and CsgB, synthesized in the cytoplasm, are highly amyloidogenic. It is imperative to keep the proteins in a soluble, non-aggregated form to prevent intracellular aggregation and cellular toxicity. Chaperones and chaperone-like proteins aid in solubility an
Curli fibrils produced by E. coli can cross-seed α-synuclein aggregation in vitro and in vivo in gnotobiotic m… STRONG▼
The intestinal microbiota influence neurodevelopment, modulate behavior, and contribute to neurological disorders. However, a functional link between gut bacteria and neurodegenerative diseases remains unexplored. Synucleinopathies are characterized by aggregation of the protein α-synuclein (αSyn), often resulting in motor dysfunction as exemplified by Parkinson's disease (PD). Using mice that overexpress αSyn, we report herein that gut microbiota are required for motor deficits, microglia activ
Chronic myeloid leukemia (CML) is caused by the acquisition of the tyrosine kinase BCR-ABL1 in a hemopoietic stem cell, transforming it into a leukemic stem cell (LSC) that self-renews, proliferates, and differentiates to give rise to a myeloproliferative disease. Although tyrosine kinase inhibitors (TKIs) that target the kinase activity of BCR-ABL1 have transformed CML from a once-fatal disease to a manageable one for the vast majority of patients, only ∼10% of those who present in chronic phas
Demonstrates that E. coli-derived CsgA peptides can stimulate microglial cytokine production and affect amyloi… MEDIUM▼
Epidemiological and pre-clinical data propose that infections can accelerate the cognitive decline in Alzheimer's disease (AD) and other dementias. The implication of infectious agents, and especially the role of E.coli and other amyloid-peptide producing bacteria, on the development and progression of cerebral amyloidosis and neuroinflammation, both key neuropathological characteristics of AD, has only been studied to a limited extent. In this study, recombinant bacterial amyloid surface protei
Growing evidence indicates that gut microbiota play a critical role in regulating the progression of neurodegenerative diseases such as Parkinson's disease. The molecular mechanism underlying such microbe-host interaction is unclear. In this study, by feeding
Emerging evidence from both clinical studies and animal models indicates the importance of the interaction between the gut microbiome and the brain in the pathogenesis of neurodegenerative diseases (NDs). Although how microbes modulate neurodegeneration is still mostly unclear, recent studies have s
Biofilm-associated amyloid proteins have emerged as significant contributors to the progression of neurodegenerative diseases, representing a complex intersection of microorganisms and human health. The cross-beta sheet structure characteristic of amyloids produced by gut-colonizing bacteria remains
✗ Opposing Evidence 3
Curli fibrils are primarily found in biofilms outside epithelial cells and may have limited access to enteric … MEDIUM▼
Pleiotropic effects of statins decrease intrahepatic resistance and portal hypertension. We evaluated the effects of simvastatin on hepatic venous pressure gradient (HVPG) and azygos vein blood flow in cirrhotic patients. A 3-month prospective, randomized, triple-blind trial with simvastatin (40 mg/day) vs. placebo was conducted in patients with cirrhotic portal hypertension. HVPG and azygos blood flow, measured by colour Doppler endoscopic ultrasound, were assessed before and after treatment. T
Anti-amyloid antibodies targeting bacterial curli may cross-react with endogenous functional amyloids in the b… MEDIUM▼
To fully exploit the potential of single-cell functional genomics in the study of development and disease, robust methods are needed to simplify the analysis of data across samples, time-points and individuals. Here we introduce a model-based factor analysis method, SDA, to analyze a novel 57,600 cell dataset from the testes of wild-type mice and mice with gonadal defects due to disruption of the genes Mlh3, Hormad1, Cul4a or Cnp. By jointly analyzing mutant and wild-type cells we decomposed our
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼
Novel Therapeutic Hypotheses for Gut-Brain Axis in Parkinson's Disease
Hypothesis 1: Bacterial Curli Amyloid Mimicry Pathway
Title: Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-SeedingDescription: Gut bacteria produce curli amyloid fibrils that structurally mimic α-synuclein and act as nucleation seeds, promoting pathological α-synuclein aggregation through molecular mimicry. Therapeutic intervention with curli synthesis inhibitors (like Congo Red derivatives) could prevent this cross-kingdom amyloid seeding and halt early PD pathogenesis.
Target: CsgA (c
🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼
Critical Evaluation of Gut-Brain Axis Hypotheses in Parkinson's Disease
Hypothesis 1: Bacterial Curli Amyloid Mimicry Pathway
Weaknesses in Evidence:
- Cross-seeding specificity: The supporting studies primarily used C. elegans models, which lack the complex human blood-brain barrier and immune system (PMID:26751493). Cross-kingdom amyloid interactions may not translate to mammalian systems.
- Causation vs. correlation: The presence of bacterial amyloids in PD patients doesn't establish causation - they could be a consequence rather than cause of gut dysbiosis.
- **Selectivi
🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼
Practical Feasibility Assessment: Gut-Brain Axis PD Hypotheses
HYPOTHESIS 1: Bacterial Curli Amyloid Inhibition
Druggability: MODERATEChemical Matter & Tool Compounds:
- Congo Red derivatives: FN-1501 (developed by Funxional Therapeutics) - synthetic Congo Red analog with improved pharmacokinetics
- Curcumin analogs: EF24, Difluorinated curcumin (showed anti-amyloid activity in preclinical studies)
- Small molecule amyloid inhibitors: Epigallocatechin gallate (EGCG), Quercetin, Resveratrol
Existing Clinical Candidates:
- **None specifically targeting bacterial
⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼
Price History
| Event | Price | Change | Source | Time | |
|---|---|---|---|---|---|
| 📄 | New Evidence | $0.516 | ▲ 1.8% | evidence_batch_update | 2026-04-13 02:18 |
| 📄 | New Evidence | $0.507 | ▲ 4.0% | evidence_batch_update | 2026-04-13 02:18 |
| ⚖ | Recalibrated | $0.488 | ▼ 0.5% | 2026-04-12 10:15 | |
| ⚖ | Recalibrated | $0.490 | ▼ 1.1% | 2026-04-10 15:58 | |
| ⚖ | Recalibrated | $0.496 | ▲ 1.3% | 2026-04-10 15:53 | |
| ⚖ | Recalibrated | $0.489 | ▲ 12.2% | 2026-04-08 18:39 | |
| ⚖ | Recalibrated | $0.436 | ▼ 0.8% | 2026-04-04 16:38 | |
| ⚖ | Recalibrated | $0.439 | ▼ 2.5% | 2026-04-04 16:02 | |
| 📄 | New Evidence | $0.451 | ▲ 2.9% | evidence_batch_update | 2026-04-04 09:08 |
| ⚖ | Recalibrated | $0.438 | ▼ 34.2% | 2026-04-03 23:46 | |
| 📄 | New Evidence | $0.666 | ▼ 0.7% | evidence_batch_update | 2026-04-03 01:06 |
| 📄 | New Evidence | $0.671 | ▲ 50.3% | evidence_batch_update | 2026-04-03 01:06 |
| ⚖ | Recalibrated | $0.446 | ▼ 36.7% | 2026-04-02 21:55 | |
| 📊 | Score Update | $0.705 | ▲ 17.5% | market_dynamics | 2026-04-02 21:38 |
| ✨ | Listed | $0.600 | market_dynamics | 2026-04-02 21:38 |
Clinical Trials (5) Relevance: 38%
Active
Completed
Total Enrolled
Highest Phase
📚 Cited Papers (30)
📓 Linked Notebooks (4)
Wiki Pages
KG Entities (51)
Related Hypotheses
Estimated Development
🧪 Falsifiable Predictions (5)
Knowledge Subgraph (200 edges)
activates (3)
associated with (15)
causes (2)
component of (1)
participates in (19)
regulates (1)
Mechanism Pathway for CSGA
Molecular pathway showing key causal relationships underlying this hypothesis
graph TD
SNCA["SNCA"] -->|encodes| alpha_synuclein["alpha_synuclein"]
NLRP3["NLRP3"] -->|associated with| neurodegeneration["neurodegeneration"]
NLRP3_1["NLRP3"] -->|interacts with| CASP1["CASP1"]
NLRP3_2["NLRP3"] -->|interacts with| IL1B["IL1B"]
NLRP3_3["NLRP3"] -->|interacts with| PYCARD["PYCARD"]
CASP1_4["CASP1"] -->|associated with| neurodegeneration_5["neurodegeneration"]
CASP1_6["CASP1"] -->|interacts with| NLRP3_7["NLRP3"]
CASP1_8["CASP1"] -->|interacts with| IL1B_9["IL1B"]
CASP1_10["CASP1"] -->|interacts with| PYCARD_11["PYCARD"]
IL1B_12["IL1B"] -->|associated with| neurodegeneration_13["neurodegeneration"]
IL1B_14["IL1B"] -->|interacts with| NLRP3_15["NLRP3"]
IL1B_16["IL1B"] -->|interacts with| CASP1_17["CASP1"]
style SNCA fill:#ce93d8,stroke:#333,color:#000
style alpha_synuclein fill:#4fc3f7,stroke:#333,color:#000
style NLRP3 fill:#ce93d8,stroke:#333,color:#000
style neurodegeneration fill:#ef5350,stroke:#333,color:#000
style NLRP3_1 fill:#ce93d8,stroke:#333,color:#000
style CASP1 fill:#ce93d8,stroke:#333,color:#000
style NLRP3_2 fill:#ce93d8,stroke:#333,color:#000
style IL1B fill:#ce93d8,stroke:#333,color:#000
style NLRP3_3 fill:#ce93d8,stroke:#333,color:#000
style PYCARD fill:#ce93d8,stroke:#333,color:#000
style CASP1_4 fill:#ce93d8,stroke:#333,color:#000
style neurodegeneration_5 fill:#ef5350,stroke:#333,color:#000
style CASP1_6 fill:#ce93d8,stroke:#333,color:#000
style NLRP3_7 fill:#ce93d8,stroke:#333,color:#000
style CASP1_8 fill:#ce93d8,stroke:#333,color:#000
style IL1B_9 fill:#ce93d8,stroke:#333,color:#000
style CASP1_10 fill:#ce93d8,stroke:#333,color:#000
style PYCARD_11 fill:#ce93d8,stroke:#333,color:#000
style IL1B_12 fill:#ce93d8,stroke:#333,color:#000
style neurodegeneration_13 fill:#ef5350,stroke:#333,color:#000
style IL1B_14 fill:#ce93d8,stroke:#333,color:#000
style NLRP3_15 fill:#ce93d8,stroke:#333,color:#000
style IL1B_16 fill:#ce93d8,stroke:#333,color:#000
style CASP1_17 fill:#ce93d8,stroke:#333,color:#000
3D Protein Structure
🧬 CSGA — Search for structure Click to search RCSB PDB
Source Analysis
What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?
neurodegeneration | 2026-04-01 | completed